TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02432118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency-Guided Localization
Description: Undergo radiofrequency-guided localization
Study: NCT00728637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Passport to Heart Health Program
Description: Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Educational Materials
Description: Participants in the control group received an educational brochure about heart health at the baseline study visit.
Study: NCT01876511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 10 mg/kg every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 10 mg/kg every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 10 mg/kg every 14 days
Study: NCT01603719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: new infant formula with prebiotics and beta-palmitate
Description: experimental infant formula as sole source of nutrition over first 12 weeks of life
Study: NCT00276250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
Study: NCT02193269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: you will receive 200 mg as a single daily dose for 4 days
Study: NCT01374841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation,
Description: Hematopoietic Stem Cell Transplantation,
Study: NCT02774954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change the Cycle
Description: See previous response
Study: NCT00276250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
Study: NCT02796651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (12 μg)
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (40 μg)
Description: Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Study: NCT02774954

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Change the Cycle
Description: See previous response
Study: NCT05655442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early APM
Description: early APM within 3 and 6 month knee pain symptoms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed APM
Description: delayed APM within 6 and 12 month knee pain symptoms
Study: NCT01196988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2321138A
Description: intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: intramuscular injections
Study: NCT01757639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT01196988

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine GSK2604409A
Description: intramuscular injections
Study: NCT01320436

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 3 capsules (820 mg containig 500 mg curcumin each) twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-aminosalicylic acid
Description: The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-aminosalicylic acid
Description: The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
Study: NCT03578640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir, Grazoprevir 50-100Mg Oral Tablet
Description: Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
Study: NCT02970708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFG group
Description: 88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching group
Description: 88 anisometropic amblyopia will be recruited to receive patching treatment.
Study: NCT02064569

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS010
Study: NCT04680702

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sims Score
Description: Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
Study: NCT04041999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Cognition Training Program
Description: Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Cognition Training Program
Description: Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc.
Study: NCT03322020

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife boost 18 Gy
Description: pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife boost 21 Gy
Description: pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
Study: NCT02427087

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aerobic Training twice
Description: Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Description: Diet group (21) Recommendation for healthy diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Description: Diet group (21) Recommendation for healthy diet.
Study: NCT03712124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNSA-001
Description: CNSA-001 Powder for Suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension
Study: NCT04593394

Intervention type: DIAGNOSTIC_TEST
Intervention: Continous laryngoscopy exercise test
Description: Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
Study: NCT02267980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhalation anesthetic agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Inhalation anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intravenous anesthetic agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Isotonic solution for placebo group
Study: NCT01316978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
Study: NCT01757639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01316978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
Study: NCT01352507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Administered Orally
Study: NCT03459131

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A with Digital Zone Optics™ contact lenses
Description: Silicone hydrogel spherical contact lenses with Digital Zone Optics™
Study: NCT01352507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered Orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Administered Orally
Study: NCT02476773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel plus GLA-AF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel plus GLA-AF
Study: NCT03430999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir
Description: Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir
Description: Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
Study: NCT03459131

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A with Digital Zone Optics™ contact lenses
Description: Silicone hydrogel spherical contact lenses with Digital Zone Optics™

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Silicone hydrogel spherical contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Silicone hydrogel spherical contact lenses
Study: NCT03736746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
Study: NCT01488825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
Study: NCT03514303

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
Study: NCT04593394

Intervention type: DIAGNOSTIC_TEST
Intervention: Continous laryngoscopy exercise test
Description: Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored

Intervention type: DIAGNOSTIC_TEST
Intervention: Continous laryngoscopy exercise test
Description: Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored

Intervention type: DIAGNOSTIC_TEST
Intervention: Overnight respiratory polygraphy
Description: Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea

Intervention type: DIAGNOSTIC_TEST
Intervention: Overnight respiratory polygraphy
Description: Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea

Intervention type: DIAGNOSTIC_TEST
Intervention: Overnight respiratory polygraphy
Description: Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
Study: NCT03514303

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
Study: NCT03838341

Intervention type: DEVICE
Intervention: AtriClip™ LAA Exclusion System
Description: The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.

Intervention type: DRUG
Intervention: Oral anticoagulation therapy
Description: Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
Study: NCT03776578

Intervention type: PROCEDURE
Intervention: swallow fuction and swallow training
Description: nasogastric tube dependence rate
Study: NCT01886937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
Study: NCT03546647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Aqua Comfort Plus Toric
Description: Daily disposable soft toric contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Aqua Comfort Plus Toric
Description: Daily disposable soft toric contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Aqua Comfort Plus Sphere
Description: Daily disposable soft spherical contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Aqua Comfort Plus Sphere
Description: Daily disposable soft spherical contact lens
Study: NCT04372134

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation therapy
Description: A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (\>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
Study: NCT03430999

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04372134

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation therapy
Description: A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (\>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
Study: NCT02878785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: DNA methyltransferase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: DNA methyltransferase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: DNA methyltransferase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: DNA methyltransferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: DNA methyltransferase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: poly ADP ribose polymerase (PARP) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talazoparib
Description: poly ADP ribose polymerase (PARP) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talazoparib
Description: poly ADP ribose polymerase (PARP) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talazoparib
Description: poly ADP ribose polymerase (PARP) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: poly ADP ribose polymerase (PARP) inhibitor
Study: NCT04430998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc L-Carnosine
Description: Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
Study: NCT04710173

Intervention type: PROCEDURE
Intervention: ECMO
Description: VV-ECMO
Study: NCT04545385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574
Description: subcutaneous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT00915278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04605412
Description: PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal